This company listing is no longer active
AusCann Group Holdings Inkomsten in het verleden
Verleden criteriumcontroles 0/6
AusCann Group Holdings's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 50.2% per year.
Belangrijke informatie
-3.6%
Groei van de winst
10.7%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 31.2% |
| Inkomstengroei | 50.2% |
| Rendement op eigen vermogen | -137.4% |
| Nettomarge | -1,224.0% |
| Laatste winstupdate | 30 Jun 2022 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe AusCann Group Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -25 | 3 | 0 |
| 31 Mar 22 | 2 | -17 | 3 | 0 |
| 31 Dec 21 | 2 | -9 | 4 | 0 |
| 30 Sep 21 | 2 | -10 | 4 | 0 |
| 30 Jun 21 | 2 | -11 | 5 | 0 |
| 31 Dec 20 | 1 | -8 | 5 | -1 |
| 30 Sep 20 | 1 | -7 | 5 | 0 |
| 30 Jun 20 | 1 | -7 | 5 | 0 |
| 31 Mar 20 | 1 | -7 | 5 | 0 |
| 31 Dec 19 | 1 | -7 | 5 | 0 |
| 30 Sep 19 | 1 | -7 | 4 | 0 |
| 30 Jun 19 | 1 | -8 | 4 | 0 |
| 31 Mar 19 | 0 | -7 | 4 | 0 |
| 31 Dec 18 | 0 | -7 | 5 | 1 |
| 30 Sep 18 | 0 | -7 | 6 | 0 |
| 30 Jun 18 | 0 | -8 | 7 | 0 |
| 31 Mar 18 | 0 | -13 | 8 | 0 |
| 31 Dec 17 | 0 | -18 | 9 | 0 |
| 30 Sep 17 | 0 | -16 | 8 | 0 |
| 30 Jun 17 | 0 | -14 | 6 | 0 |
| 31 Mar 17 | 0 | -11 | 7 | 0 |
| 31 Dec 16 | 0 | -7 | 7 | 0 |
| 30 Sep 16 | 0 | -6 | 6 | 0 |
Kwaliteitswinsten: AC8 is currently unprofitable.
Groeiende winstmarge: AC8 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AC8 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Versnelling van de groei: Unable to compare AC8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: AC8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement op eigen vermogen
Hoge ROE: AC8 has a negative Return on Equity (-137.39%), as it is currently unprofitable.